Close Menu


Joseph DeSimone, Lin He

Rosetta also said that CEO Amir Avniel intends to step down in order to take the reins of Rosetta’s roughly year-old plant biotechnology unit, Rosetta Green. The disclosures were made as the company reported its second-quarter financial results.

So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.

IP Update: Sep 10, 2009


USPTO Publishes One Patent, Six Patent Applications Related to RNAi

Rosetta's loss rose sharply on increased SG&A spending and losses associated Parkway Clinical Labs, which the firm recently sold. It also announced plans for a cleantech division.

AXA Diagnostics will market the miRview cancer tests in Italy.

A team of researchers from MD Anderson Cancer Center has published a proof-of-principle study demonstrating the usefulness of miRNA biomarkers in the blood for detecting pancreatic cancer.

Of that total, more than $2 million has been handed out to finance therapeutic RNAi research, including the development of new delivery approaches and treatments for HIV-1 and amyotrophic lateral sclerosis.

Papers of Note: Sep 3, 2009


RNAi-Related Papers Published August 2009

A Santaris official also said that while the company remains committed to microRNAs as drug targets, the company isn’t likely to advance additional miRNA drugs into the clinic in the near term as it takes a measured approach to selecting future clinical candidates.


Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.